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use and costs were obtained from 5000 randomized hospital records from the Social 
Security Mexican Institute(IMSS) and ofﬁ cial institutional databases. Costs include 
outpatient and inpatient services, drug, procedures, etc. The model was validated 
according to international guidelines. Probabilistic sensitivity analyses were performed 
employing bootstrapping techniques and acceptability curves were constructed. 
RESULTS: The highest percentage of patients with no or mild pain during the follow-
up period was obtained by pregabalin(44.8%; CI95% 42.8%–48.0%); followed 
by gabapentin(38.1%; CI95% 33.2%–43.5%); duloxetine(34.2%; CI95% 27.8%–
40.6%) and amitriptyline(22.2%; CI95% 21.0%–24.0%).The annual expected
mean costs per patient were US$1503.2(US$1472.2–US$1534.09); US$1,742.7
(US$1,715.1–US$1,770.2); US$2,046.6(US$2018.6–US$2074.7) and US$643.6(US$615.2–
US$673.5), respectively. The ICER of pregabalin vs. amitriptyline(basecase) was
US$3798.9(US$3336.1–US$4,325.9). Other treatments were dominated by pregaba-
lin. Second-order Monte Carlo sensitivity analyses indicated that pregabalin would be 
a cost-saving strategy in a range of 60%–70% within accepted thresholds(p  0.05). 
CONCLUSIONS: In Mexico, pregabalin showed to be a cost-effective and cost-saving 
therapy when compared with amitriptyline and other usual treatments in the manage-
ment of FM.
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OBJECTIVES: Haemophilia A is a hereditary genetic disorder with a relatively high 
burden of disease from the perspective of both society and the individual patient. 
Kogenate FS is a second-generation full-length recombinant factor VIII (FVIII), pro-
duced without the addition of human albumin during formulation. It shows lower
incidence of inhibitors compared with other recombinant factor VIII products, which 
has an impact on economic evaluation because the haemophilia patients with inhibi-
tors have to be treated with a signiﬁ cantly higher dosage or expensive bypassing
agents. The main objective of this study is to conduct economic evaluation of Kogenate
FS compared with Recombinate in haemophilia A patients in Korea. METHODS: A 
cost-minimization analysis was performed under the assumption that Kogenate FS and 
Recombinate were clinically equivalent for treating bleeding episodes. A decision-
analytic model was developed to estimate the lifetime costs by reﬂ ecting each different 
treatment strategies for haemophilia A patients with inhibitors or not. If patients had
inhibitors, it was ramiﬁ ed according to the inhibitor titres into one of three pathways: 
5BU, 5–10BU, and 10BU. The analysis was conducted based on the societal perspec-
tive, and costs were discounted at 5% annually. Sensitivity analyses were performed
on crucial parameters. RESULTS: Incidence of inhibitor for Kogenate FS and Recom-
binate were 8.113% and 16.9% respectively. Using the base case analysis, the expected 
cost for Kogenate FS was US$1,979,133 compared with $2,382,332 for Recombinate.
So, Kogenate FS is $403,199 lower than Recombinate during lifetime. The differences
were mainly due to the higher inhibitor treatment costs. One-way sensitivity analysis 
revealed stable across included parameters. CONCLUSIONS: This cost minimization
study identiﬁ ed that treatment of Kogenate FS appears to save costs compared with
treatment of Recombinate. By initiating and continuing Kogenate FS treatment, the 
economic burden associated with Haemophilia A can be reduced under Korean health 
care system.
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OBJECTIVES: To perform economical evaluation of darbepoetin alfa vs. epoetin
alfa in hemodialysis patients with anemia and chronic kidney disease. METHODS:
The modeled study was performed. Proportion of patients receiving alternative
eritropoesis-stimulating proteins (ESP) dosing regimen, efﬁ cacy and safety of drugs
were extracted from multicenter randomized study made by Nissenson et al (American 
Journal of Kidney Diseases 2002; 1:110–8). Cost of treatment with ESPs for 28 weeks
and cost-minimization ratio (CMR) were calculated from the Russian reimbursement 
system point of view. RESULTS: According to selected study, the efﬁ cacy and safety
proﬁ le of darbepoetin alfa was similar to that of epoetin alfa. Mean dose decrease 
from 63.18 Mg/wk to 54.18 Mg/wk was observed in darbepoetin alfa group, while mean 
dose increase from 12,706 to 13,639 was registered in epoetin alfa group during 28
weeks. The costs of used medications were the same for darbepoetin alfa and epoetin 
alfa (RUB230,148.1 vs. RUB 229,427.19 (USD7,292.4 vs. USD7,269.56). The cost 
of medical manipulations were less for darbepoetin alfa due to its reduced dosing fre-
quency (RUB2284.8 vs. RUB6854.8 (US$72.4 vs. USD217.2) accordingly). Cost-
minimization analysis showed that cost of treatment with darbepoetin alfa is less then
epoetin alfa (CER  RUB3384.7 (US$107.3)). Sensitivity analysis was made on the 
basis of model, constructed with data extracted from other study (Molina et al.,
Nephrologia 2004; 6). It conﬁ rmed the results of present work. CONCLUSIONS:
According to the model darbepoetin alfa seems to be as effective and safe as epoetin
alfa, but it takes fewer costs for treatment of anemia in hemodialysis patients with
chronic kidney disease due to low dosing frequency and dose saving effect.
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OBJECTIVES: To quantify the effect of obesity on the total direct medical expenditure 
and health related quality of life in the population of the United States. METHODS:
Data from the MEPS’s Household Component (2006), a nationally representative 
survey of the U.S. civilian non-institutionalized population, was used. Analysis
accounted for the survey’s clusters, strata and sampling weights. Obesity was deﬁ ned
as body mass index q30. Direct medical expenditure attributable to obesity was esti-
mated under diverse econometric models to assess sensitivity to zero-mass, non-nega-
tive values and skewed distribution. Models compared were ordinary least-squares
(OLS) on raw and log-transformed expenditures (homoskedastic and heteroskedastic 
re-transformations), and generalized linear models (GLM) with log-link and Gamma/
Poisson families, including 2-part variants of these 5 models. Box-Cox test and Modi-
ﬁ ed Park’s test determined the link and family in the GLM models. LINK, RESET, 
Hosmer-Lemeshow and Pearson’s correlation test determined model ﬁ t, while Copas
test was employed for over-ﬁ tting and cross validation. Incremental expenditure from 
the method of recycled predictions summed over population with obesity gave the 
total expenditure. Impact of obesity on SF12 mental and physical health component 
was assessed by OLS. Covariates included age, gender, race, ethnicity, income, geo-
graphic-location, and comorbidity. RESULTS: The 2-part model of OLS on raw
expenditure was the only model to pass all the speciﬁ cation and cross-validation tests.
Based on this model, annual incremental expenditure of obesity was $1188.50 (95%
CI  $1183.70 to $1193.40). Total direct expenditure of obesity was $72 billion (95%
CI  $68.2 to $75.8 billion), nearly 3-fold increase compared to 1998 estimates. SF12
physical component score was lower by 3.7 (p  0.001) while the mental component
score was lower by 1.2 (p  0.001) for those with obesity. These decrements are similar
to those observed for diabetes or hypertension. CONCLUSIONS: Obesity exerts an 
enormous economic and humanistic burden on the U.S. civilian non-institutionalized
population.
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OBJECTIVES: To estimate the prevalence of asthma with obesity and the annual
medical costs attributable to obesity. METHODS: The cross-sectional analysis 
was conducted from adults aged 18–74 who participated in the 2003–2006 
Medical Expenditure Panel Survey. Total of 6670 asthma patients were identiﬁ ed
based on the self reported diagnosis or ICD-9-CM code of 493 after excluding 
patients with pregnancy, malignancy, kidney dialysis, immunodeﬁ ciency, or body-
mass-index(BMI) 18.5. These patients were classiﬁ ed as normal (BMI:18.5-25) or 
obese(BMI:q30). Total medical costs included ofﬁ ce based physician/outpatient visits, 
emergency room visit, or hospitalization except dental problems and injuries. Costs 
related to respiratory system diseases were costs associated with ICD-9-CM of 460–
516. The medical cost attributable to obesity was the difference between the observed 
cost and the predicted cost which was calculated using the parameters estimated from
obese patients. The parameters for obese patients were estimated using a generalized
linear model with a log link function and a gamma distribution after adjusting for
demographic, social-economic, and co-morbidity variables. All costs were converted 
to 2006 U.S. dollars using price indices. Data were analyzed using SAS/STATA. 
RESULTS: The age-adjusted prevalence of asthma in total population was 8.2% and 
that of asthma with obesity was 2.8% respectively. The average total medical treat-
ment costs in obese asthma patients were $5090 (95%CI:$4639–$5540), signiﬁ cantly 
higher than normal weight patients ($2,825;95%CI:$2291–$3359:p  0.001). After 
adjustments, the total medical costs attributable to obesity per patient were $3,960
(95%CI:$3,693–$4,228). Of that cost, $154 was attributable to respiratory system
diseases (95%CI:$48–$259) with the biggest increment in patients aged 65–74 old. 
CONCLUSIONS: Obesity is prevalent in general population as well as asthma
patients. The average medical cost attributable to obesity was signiﬁ cantly higher than 
normal weight asthma patients. Effective public programs aiming at educating the
importance of controlling weight are strongly recommended to diminish the economic
burden of obesity.
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OBJECTIVES: Although opioids have not demonstrated efﬁ cacy in treating ﬁ bromy-
algia (FM) and pose a risk for addiction, they are commonly used to treat FM patients. 
This study assesses the mean annual per patient cost of FM-related opioid use in 
commercially insured FM patients. METHODS: Using the Thomson/Medstat Mar-
ketScan Commercial Claims Database, we identiﬁ ed all patients aged 18 years with 
continuous health plan eligibility in 2006 and q1 inpatient or q2 outpatient paid 
medical claims in calendar year 2006 with ICD-9-CM diagnosis code 729.1 (“FM
patients”). Rx medications designated as possibly related to FM treatment (“FM-
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related”) included opioids, anticonvulsants, nonsteroidal anti-inﬂ ammatory drugs
(NSAIDs), salicylate analgesics, antimigraine agents, muscle relaxants, corticosteroids, 
benzodiazepines, sedatives/hypnotics, tricyclic antidepressants, serotonin-norepineph-
rine reuptake inhibitors (SNRIs), and selective serotonin reuptake inhibitors (SSRIs). 
Mean annual costs per patient were calculated using third-party payments for Rx drug
claims. RESULTS: A total of 77,124 patients met all study entry criteria. Of these FM 
patients, 40,951 (53.1%) had evidence of receipt of opioids in 2006. Total mean
annual Rx drug costs per patient were $2225.92. FM-related Rx drugs represented 
$912.80 (41.0%) of these costs. Opioids were the most costly drug class, accounting
for $272.79 (29.9%) of FM-related Rx drug costs. The next most costly drug class
was anticonvulsants at $112.90 (12.4%), followed by SNRIs at $105.14 (11.5%) and
SSRIs at $78.53 (8.6%). CONCLUSIONS: Given the widespread use of opioids, their 
lack of efﬁ cacy, and their potential for addiction, reducing opioid use may beneﬁ t
patients and reduce costs. New disease management methods and more effective 
medications to treat FM may assist in achieving this goal.
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OBJECTIVES: To measure the long-term cost consequences of using recombinant 
activated factor VII (rFVIIa) in total hip replacement in haemophilia patients with 
inhibitors in a Swedish setting. Severe haemophilic arthropathy has a negative impact
on health-related quality of life due to recurrent bleeds, chronic pain and signiﬁ cantly 
reduced mobility. Successful Elective Orthopaedic Surgery (EOS) of an affected joint 
can lead to decreased bleed frequency into the new joint, less time spent in hospital, 
relief of chronic pain, and increased mobility and health-related quality of life. 
METHODS: A decision-analytic model was designed to assess cost implications of 
using rFVIIa in haemophilia patients with inhibitors who are candidates for surgery. 
It is based on a consensus protocol from an “Elective Orthopaedic Surgery (EOS)
Expert Group” convened in London in 2006. The model calculates costs of surgery
in a ﬁ ve-year perspective, based on data of bleed reduction of 80–89% in the joint 
during the years after surgery. One-way sensitivity analyses were made, varying patient
weight (55–95 kg), length of stay in hospital (8–16 days), number of physiotherapy 
sessions (6–24), number of bleeds in the affected joint over the past 12 months (6–14),
and bleed reduction assumption (70–90%). A unit cost of SEK 5822/mg for rFVIIa 
was used (USD 1  SEK 7.86). RESULTS: Total hip replacement was cost-saving in
the fourth year after surgery, and in a ﬁ ve-year perspective, savings were SEK1,315,749. 
In the sensitivity analyses, surgery was cost-saving within three to ﬁ ve years. The only
exception was seen in patients who had 6 bleedings or less in the affected joint during 
the year preceding surgery. CONCLUSIONS: In a ﬁ ve-year perspective, total hip
replacement using rFVIIa is cost-saving for haemophilia patients with inhibitors who
had more than six bleedings in the affected joint during the previous year prior to 
surgery.
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OBJECTIVES: To estimate the economic burden of diabetes, hypercholesterolemia 
and hypertension related to overweight and obesity in Mexican children aged between 
ﬁ ve and eleven years during their life-time. METHODS: A Discrete Event Model was 
designed to calculate prevalence and yearly incidence of diabetes, hypercholesterol-
emia and hypertension and its related costs during the life-time of a children cohort
aged between ﬁ ve and eleven at the start of the simulation. The size of the cohort is 
one of one thousand of the total population reported by the Mexican Population
Council for that age range. Data of risk of dying at each age was obtained from the
same source and a 0.2% was added for each comorbidity. Costs were obtained from 
the Popular Insurance report of 2001. Due to the absence of data related to incidence 
of comorbidities in overweight and obese children, adult data was used but smoothed
by an exponential curve. Probability of becoming overweight and obese was obtained 
from the National Health and Nutrition Survey of 2006. A 3% discount rate was used
for all costs. Results are presented in US dollars with an exchange rate of 13.5 MXN 
pesos for 1 US dollar. RESULTS: Total expenditure in comorbidities for children that 
became obese at any time during simulation was $96,632,485,372, for those who
became overweight was $90,513,280,890 and for those that remain in normal weight 
was $55,650,160,294. CONCLUSIONS: From the results of the model it can be said 
that for the group of children currently aged between 5 and 11 years an extra $ 41 
billion will be spend in comorbidities of those that will become obese and an extra $ 
35 billion for those that will become overweight compared to those that will remain 
in a normal weight.
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OBJECTIVES: Contracts with physicians or institutes that perform health care 
services can provide price advantages due to competition. The sickness funds of 
the Austrian Social Security signed different contracts concerning haemograms with
physicians or institutes. Claims data, respectively rendered fees suggest a possible 
savings potential in the fee for service system without reducing the scope of the 
procedures or the frequencies. We analyzed the variety of prices in the ﬁ eld of hae-
mograms including contracted physicians and institutes. This shows variability among
the total amount of reimbursement in the Austrian outpatient sector consisting of 
contracted physicians, institutes, and outpatient clinics of hospitals and ambulatories. 
The outpatient sector is supplied with services by contracted physicians. Approxi-
mately 30% of the Austrian outpatient sector cannot be displayed since no data is
available from outpatient clinics of hospitals. METHODS: Price differences for the 
same or similar procedures performed by different contracted physicians or institutes
are evaluated. Different ﬁ nancial impacts (e.g. focusing on average or lowest value)
are simulated. Values were rounded to two decimal points, however, calculated by 15 
decimal points. The fee equals the division of turnover and frequency. RESULTS:
Services in haemograms were brought into account 103,468,542 times in the year 
2006. Calculating all frequencies with the lowest paid fee (turnover/frequency) for 
each service would lead to a lower ﬁ nancial effort of 82% compared to the current
turnover. Calculating all frequencies with the highest fee for service would lead to a
higher effort of 117% compared to the current turnover. CONCLUSIONS: A current 
savings potential of 117%, contrasting the current fee with the most expensive one,
indicates a well established fee negotiation. However, a savings potential of 82% is
worth being considered for further evaluation and, if necessary, the adjustment of fees 
is advisable.
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OBJECTIVES: Fibromyalgia is a chronic condition characterized by widespread
pain and decreased physical function. This study compares the economic burden
in patients diagnosed with Fibromyalgia (FM) with that of patients diagnosed 
with Chronic Fatigue Syndrome (CFS) and patients with Major Depressive Disorder
and other Depressive Disorders (DEP). METHODS: Claims data were obtained
from the Thomson/Medstat MarketScan Commercial Claims Database. Study subjects
aged 18 with continuous eligibility were required to have q1 inpatient claim or
q2 outpatient claims during 2006 with ICD-9-CM codes for one of the disease condi-
tions. Patient groups were not mutually exclusive (1.0% of FM patients had CFS and 
10.8% had DEP). Mean annual third-party payer costs/patient were calculated based
on paid claims. Incremental costs relative to FM were generated using generalized 
linear models (family  gamma, link  log), adjusting for age, gender, beneﬁ ciary
status, employment status, insurance plan type, comorbid prevalence of FM, DEP, 
CFS, and other comorbidities. RESULTS: A total of 77,124 FM, 11,672 CFS and 
215,380 DEP patients met all study entry criteria. Total unadjusted costs for FM 
patients ($10,187) were similar to that of DEP patients ($10,416) and greater than 
CFS patients ($8,314). The highest unadjusted cost category for all patients were 
outpatient costs (FM $5594; DEP $4972; CFS $4605), followed by inpatient costs 
(FM $2367; DEP $3136; CFS $2067). Prescription costs (FM $2226; DEP $2308,
CFS $1641) were the lowest cost category. After adjusting for covariates, third-party 
payer costs for FM patients were not signiﬁ cantly different than costs for CFS patients
and were 9% ($984) lower costs for DEP patients. CONCLUSIONS: The costs to 
treat FM patients are high and comparable to that for CFS and DEP, other chronic
diseases with similar symptoms and/or often covered by third-party payers. Early 
diagnosis and use of effective treatments for FM could reduce the economic burden 
on third-party payers.
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OBJECTIVES: Examine the real-world role of duloxetine vs. other treatment for low 
back pain (LBP). METHODS: 500 patients, ages 18–64 years, with 1 LBP diagnosis, 
as speciﬁ ed by HEDIS, and 1 duloxetine prescription within a year after LBP diag-
nosis were identiﬁ ed from a large, privately-insured claims database (5 million lives; 
2004–2006). Patients had continuous eligibility 6 months after their index duloxetine
prescription (study period) and 6 months before their index prescription (baseline
period) and no other duloxetine prescription during the baseline period. Duloxetine-
treated patients were matched to 500 LBP patients (controls) who initiated another
pharmacological or non-invasive LBP treatment in the same month from LBP diagno-
sis as duloxetine was initiated in duloxetine-treated patients. Controls were also
matched using baseline propensity scores of duloxetine treatment, speciﬁ c comorbidi-
ties, LBP diagnostic categories and baseline LBP treatments. Patients with back surgery 
prior to index date were excluded. McNemar tests were used to compare study period 
